SpinalCare Physical Medicine Announces New Migraine

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SpinalCare Physical Medicine Announces New Migraine Treatment

AVON, Ind., Nov. 17, 2013 (GLOBE NEWSWIRE) -- SpinalCare Physical Medicine is now offering the Sphenopalatine Nerve Block treatment as part of their multi-dimensional approach to migraine and chronic headache treatment. According to Dr. John Dettmer, D.C. the Sphenopalatine Nerve Block treatment is an effective way to manage chronic migraines and headaches because the treatment addresses the underlying cause for headache pain. This is different from treatments that rely primarily on medication to "cover up" pain but fail to address the root causes. Dr. Dettmer says that a multi-disciplinary approach to headache and migraine pain management delivers optimal results for patients.

Chronic headache and migraine sufferers now have access to a new treatment option, known as Sphenopalatine Nerve Block treatment . It is available through SpinalCare Physical Medicine, a multi-dimensional health and wellness center.

"Sphenopalatine Nerve Block treatment is extremely effective for managing chronic migraine and headache pain, especially when this pain is recurring and fails to respond to other treatments," said Nurse Practitioner James Franklin.

"We have a 95% success rate using this procedure. Pain is reduced with 30-120 seconds usually with a complete or nearly complete resolution or symptoms," claims Franklin.

Migraine headaches are one of the most common medical complaints. One out of every six people each year suffers from migraine pain, and millions of other individuals also experience cluster and tension headache pain.

"Migraines can be caused by reduced blood flow to various areas of the cerebral cortex," said Dr. Dettmer. "One way to treat migraine headache pain is to help restore this blood flow and prevent future impediments. By integrating pain management and physical therapy with chiropractic care, we are able to deliver optimal results for our patients."

In addition to multi-dimensional therapies, SpinalCare Physical Medicine provides complete and thorough diagnostic testing.

"Our diagnostic tests allow us to precisely identify the root cause for pain and then aggressively treat this cause," said Dr. Dettmer. "From the first day of treatment to the last day of our patients' pain relief program, we provide comprehensive migraine and headache pain management. Most importantly, we never rely on medication to 'mask' pain symptoms; we always address the root cause for health problems."

According to Dr. Dettmer, individuals can also help lower their risk for migraines by avoiding stress, getting enough sleep, and not skipping meals. Some individuals may also benefit by avoiding so-called "trigger" foods and certain types of alcohol, such as red wine. Dr. Dettmer provides lifestyle counseling to help patients identify trigger foods and remove these foods from their diets.

SpinalCare Physical Medicine is a pain management, physical medicine and chiropractic facility. The practice provides spinal decompression therapy , deep tissue laser therapy, trigger point injections, joint injections, kinesiology taping and advanced cranial therapeutic correction.

To learn more about the practice's approach to treating migraines and chronic headaches, including Sphenopalatine Nerve Block treatment, visit http://spinalcareavon.com/ .

SpinalCare Physical Medicine 888-667-5235

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 20

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 22

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 16

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 10

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 25

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 11

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 21

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Thermo Fisher's Role as the Leading Partner in Biopharma

Updated Category News Views 212

Thermo Fisher's Role in Revolutionizing Biopharma Thermo Fisher Scientific Inc. (TMO) is increasingly becoming the cornerstone of the biopharma sector. Although some analysts have observed a recent dip in its stock performance, there is a strong belief in its capability to rebound through strategic acquisitions and promising growth prospects. Notably, Thermo Fisher boasts...

Continue Reading
Jamf Unveils Comprehensive Reinvestment Strategy for Growth

Updated Category News Views 161

Jamf's Strategic Reinvestment Initiative In a bold move aimed at enhancing operational efficiency and shareholder value, Jamf (NASDAQ: JAMF) has announced a strategic reinvestment plan designed to propel long-term growth. This initiative comes on the heels of a comprehensive systems update that has illuminated new business opportunities and operational insights. Enhancing...

Continue Reading
Fidelity D & D Bancorp, Inc. Sees Earnings Impact in Q3

Updated Category News Views 46

Fidelity D & D Bancorp, Inc. Announcements on Financial Standing In recent news regarding Fidelity D & D Bancorp, Inc. (NASDAQ: FDBC), the company revealed its latest financial results, marking a significant quarter in their ongoing operations. As of September 30, 2024, Fidelity Bank, under the leadership of President and CEO Daniel J. Santaniello, has recorded key...

Continue Reading
Deutsche Bank Lowers Boeing Price Target, Retains Buy Rating

Updated Category News Views 71

Deutsche Bank's Strategic Assessment of Boeing Recently, Deutsche Bank has made headlines with its updated financial outlook for Boeing (NYSE: BA), decreasing the stock price target from $225.00 to $195.00. However, they have maintained a Buy rating on the aerospace company's shares. This adjustment comes in response to expected larger free cash flow (FCF) burn for the...

Continue Reading
TIGRIS Aquatic Services Expands With LakePro Acquisition

Updated Category News Views 868

TIGRIS Aquatic Services Expands With LakePro Acquisition TIGRIS Aquatic Services, LLC has made a significant move by acquiring LakePro, Inc., a prominent player in the field of aquatic management. This acquisition opens new opportunities for TIGRIS, expanding its operational reach into fresh markets and reinforcing its commitment to creating safe and well-managed water...

Continue Reading